With 5.85M shares out, PCHM has 12-month EPS of $.17, and $.50/share in cash
And these two items from the new shareholder letter bode well for the future, IMO:
Our growth in 2017 is expected to ease somewhat but still achieve a double digit increase in sales.
We continue to explore opportunities to present PharmChem, its franchise and strategic value to those companies that can benefit from acquiring us at the appropriate valuation.
Government is never more dangerous than when our desire to have it help us blinds us to its great power to harm us.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.